N C Biesma

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Hjalmar C. van Santvoort · 8 shared papers, 2023–2026 · strength 1.84
   • Paper Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Populati… DOI 10.1002/jso.70391↗
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. DOI 10.1007/s12029-025-01357-y↗
2. Lois A. Daamen · 6 shared papers, 2023–2026 · strength 1.36
   • Paper Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Populati… DOI 10.1002/jso.70391↗
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. DOI 10.1007/s12029-025-01357-y↗
3. Izaak Quintus Molenaar · 6 shared papers, 2023–2026 · strength 1.36
   • Paper Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Populati… DOI 10.1002/jso.70391↗
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. DOI 10.1007/s12029-025-01357-y↗
4. Johanna W. Wilmink · 5 shared papers, 2025–2026 · strength 1.10
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
   • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗
5. Judith de Vos‐Geelen · 5 shared papers, 2025–2026 · strength 1.10
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
   • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗
6. Robert C. Verdonk · 4 shared papers, 2025–2026 · strength 0.93
   • Paper Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Populati… DOI 10.1002/jso.70391↗
   • Paper Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. DOI 10.1007/s12029-025-01357-y↗
   • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
7. Marc G. Besselink · 4 shared papers, 2025–2026 · strength 0.87
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
   • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
8. Ignace H. J. T. de Hingh · 3 shared papers, 2026 · strength 0.68
   • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
   • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗
   • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
9. Bas Groot Koerkamp · 3 shared papers, 2025–2026 · strength 0.62
   • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
   • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
   • Paper Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert s… DOI 10.1016/j.ejso.2024.109544↗
10. Lydia G. van der Geest · 2 shared papers, 2026 · strength 0.51
    • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
11. Marjolein Y.V. Homs · 2 shared papers, 2026 · strength 0.48
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
    • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗
12. Casper H.J. van Eijck · 2 shared papers, 2026 · strength 0.46
    • Paper The impact of lower household income and distance to hospital on treatment and survival in patients with localized panc… DOI 10.1016/j.ejca.2026.116956↗
    • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
13. Vincent Erwin de Meijer · 2 shared papers, 2026 · strength 0.44
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
    • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
14. Bert A. Bonsing · 2 shared papers, 2026 · strength 0.44
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
    • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
15. Merlijn U.J.E. Graus · 2 shared papers, 2025–2026 · strength 0.40
    • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗
    • Paper Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert s… DOI 10.1016/j.ejso.2024.109544↗
16. Iris W.J.M. van Goor · 2 shared papers, 2023–2026 · strength 0.36
    • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
    • Paper Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-instit… DOI 10.1016/j.ejso.2023.04.009↗
17. Vincent P. Groot · 2 shared papers, 2023–2026 · strength 0.36
    • Paper Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. DOI 10.1016/j.ejso.2025.111165↗
    • Paper Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-instit… DOI 10.1016/j.ejso.2023.04.009↗
18. Nadia Haj Mohammad · 1 shared paper, 2026 · strength 0.32
    • Paper Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Populati… DOI 10.1002/jso.70391↗
19. Peter G. Noordzij · 1 shared paper, 2025 · strength 0.26
    • Paper Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. DOI 10.1007/s12029-025-01357-y↗
20. Simone Augustinus · 1 shared paper, 2026 · strength 0.24
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
21. Jeanin Elise van Hooft · 1 shared paper, 2026 · strength 0.24
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
22. Marion B.M. van der Kolk · 1 shared paper, 2026 · strength 0.24
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
23. Thijmen H.T. Broekman · 1 shared paper, 2026 · strength 0.24
    • Paper Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide … DOI 10.1016/j.hpb.2025.12.035↗
24. Ruth A.L. Willems · 1 shared paper, 2026 · strength 0.24
    • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗
25. A.J. de Wilde · 1 shared paper, 2026 · strength 0.24
    • Paper Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemothera… DOI 10.1016/j.esmogo.2026.100311↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.